UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vandetanib for the Treatment of Thyroid Cancer

Clinical pharmacology and therapeutics, 2012-01, Vol.91 (1), p.71-80

2012

Volltextzugriff (PDF)

Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question

The Journal of immunology (1950), 2001-01, Vol.166 (2), p.973-981

2001

Volltextzugriff (PDF)

P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL LYMPHOMA (CITADEL‐112): PRELIMINARY SAFETY RESULTS

HemaSphere, 2022-06, Vol.6 (Suppl), p.992-993

2022

Volltextzugriff (PDF)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

HemaSphere, 2022-06, Vol.6 (Suppl), p.994-995

2022

Volltextzugriff (PDF)

PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells

Blood, 2000-02, Vol.95 (3), p.879-885

2000

Volltextzugriff (PDF)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

The lancet oncology, 2010-07, Vol.11 (7), p.619-626

2010

Volltextzugriff (PDF)

P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

Annals of oncology, 2021-07, Vol.32, p.S137

2021

Volltextzugriff (PDF)

6609 POSTER Vandetanib in advanced non-small-cell lung cancer: an ongoing clinical evaluation programme

European journal of cancer supplements, 2007, Vol.5 (4), p.390-391

2007

Volltextzugriff (PDF)

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Clinical cancer research, 2004-06, Vol.10 (11), p.3650-3657

2004

Volltextzugriff (PDF)

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

European journal of cancer supplements, 2009, Vol.7 (2), p.506-506

2009

Volltextzugriff (PDF)

Acute myeloid leukaemia in children

Best practice & research. Clinical haematology, 2001-03, Vol.14 (1), p.77-93

2001

Volltextzugriff (PDF)

Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7525-7525

2010

Volltextzugriff (PDF)

Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7516-7516

2010

Volltextzugriff (PDF)

862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

European urology supplements : official journal of the European Association of Urology, 2014-04, Vol.13 (1), p.e862-e862

2014

Volltextzugriff (PDF)

Bone marrow abnormalities in the non-obese diabetic mouse

International immunology, 1993-02, Vol.5 (2), p.169-177

1993

Volltextzugriff (PDF)

Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5510-5510

2011

Volltextzugriff (PDF)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Journal of clinical oncology, 2009-06, Vol.27 (18S), p.CRA8003-CRA8003

2009

Volltextzugriff (PDF)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Journal of clinical oncology, 2009-06, Vol.27 (18_suppl), p.CRA8003-CRA8003

2009

Volltextzugriff (PDF)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.CRA8003-CRA8003

2009

Volltextzugriff (PDF)

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8009-8009

2009

Volltextzugriff (PDF)

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8010-8010

2009

Volltextzugriff (PDF)

Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.6016-6016

2009

Volltextzugriff (PDF)

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.8009-8009

2008

Volltextzugriff (PDF)

Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3065-3065

2004

Volltextzugriff (PDF)

Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3065-3065

2004

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(97)
Japanisch
(16)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Vandetanib for the Treatment of Thyroid Cancer

Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question

P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL LYMPHOMA (CITADEL‐112): PRELIMINARY SAFETY RESULTS

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

6609 POSTER Vandetanib in advanced non-small-cell lung cancer: an ongoing clinical evaluation programme

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

Acute myeloid leukaemia in children

Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR)

Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC

862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

Bone marrow abnormalities in the non-obese diabetic mouse

Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)

Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC)

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent

Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent

Suchergebnisse filtern